NCT05140746Recruiting
Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
A Prospective Study on Predicting the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
Source: ClinicalTrials.gov · Last updated 9 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study intends to explore the value of 68Ga-FAPI-04 and 18F-FDG PET/CT in the evaluation of treatment response to neoadjuvant chemotherapy(NAC) for patients with locally advanced gastric cancer(LAGC).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 8 Nov 2021
- Start date
- 10 Sept 2020
- Primary completion date
- 10 Sept 2024
- Lead sponsor
- Ruijin Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05140746
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 10 Sept 2020 to the primary completion date, 10 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- With second primary malignant diseases in past five years, exceptions include basal cell and squamous cell carcinoma of the skin that have been cured.
- Known hypersensitivity reaction to chemotherapy drugs or with contraindications.
- With severe disease or other unsuitable conditions determined by investigators. Inadequate organ function.
Lab values
- With uncontrollable diabetic or fasting blood glucose level ≥11 mmol/L on the test-day.
Other
- With severe mental symptoms, unconscious or unable to complete the examination.
- Pregnancy or possibly pregnant woman, breastfeeding woman.
- Lack of compliance.
Who the study is looking for
- Age between 18-75 years.
- Histologically confirmed gastric adenocarcinoma through gastroscopy.
- Resectable gastric cancer.
- ECOG performance status 0-1.
- White blood count \>4x109/L, Absolute neutrophil count (ANC) \>2x109/L, Hemoglobin (Hb)\>90g/L, Platelets \>100x109/L.
- Ejection Fraction\>50%.
- Serum bilirubin \<1.5x ULN; ALT and AST \<1.5x ULN.
- Serum creatinine ≤1.5x ULN, or GFR\> 60ml/min.
- Agreement to participate in this study with informed consent form.
- Willingness and ability to comply with the protocol for the duration of the study.
- No children bearing petential in the next six months before enrollment.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Ruijin Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.